Clinical trials: Fibrotic Lung Disease
Hypersensitivity Pneumonitis
"Randomized Controlled Trial Testing the Efficacy of Corticosteroid Therapy Versus Placebo in Fibrotic Hypersensitivity Pneumonitis"
Hypersensitivity Pneumonitis (HP) is an immune-mediated disease that manifests as interstitial lung disease after exposure to an inhaled antigen, often unidentified. HP can be classified as non-fibrotic or fibrotic HP.
- Trial name
- RUBY (NCT07210008)
- Testing
- Prednisolone
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Graft-versus-host Disease
Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children
In this study we will combine mycophenolate mofetil and imatinib mesylate to treat steroid-refractory sclerotic/fibrotic type chronic graft-versus-host disease (GVHD) to see the response rate and to find the safety of combination.
- Trial name
- NCT01898377
- Testing
- Imatinib mesylate, Mycophenolate mofetil
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Seoul National University Hospital
Pulmonary Fibrosis, Interstitial Lung Disease
The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19
Up to a third of patients who recovered from SARS coronavirus (SARS-CoV) had a 20% decline in lung function with a long term reduction in exercise capacity and SF-36 health status a year after infection.
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Covid19
- Trial name
- MONACO (NCT04805086)
- Testing
- MON002
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Pulmonary Fibrosis, Interstitial Lung Disease
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of…
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Trial name
- ENDCOV-I (NCT04619680)
- Testing
- Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Scleroderma, Systemic, Interstitial Lung Disease
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).
- Trial name
- SLSIII (NCT03221257)
- Testing
- Pirfenidone (PFD), Mycophenolate Mofetil (MMF)
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- Michael Roth
Interstitial Lung Disease
Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis
Patients are being offered participation in this pirfenidone trial because They have been diagnosed with fibrotic hypersensitivity pneumonitis (FHP), a type of interstitial lung disease (ILD).
- Trial name
- NCT02958917
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Evans Fernandez Perez
Idiopathic Pulmonary Fibrosis
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
- Trial name
- NCT05779007
- Testing
- Pirfenidone, Nintedanib
- Where
- United States
- Volunteers
- 2,778 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
The planned study is a prospective cohort interventional study in IPF and PF-ILD patients after initiating anti-fibrotic therapy and pulmonary rehabilitation.
- Trial name
- Actigraphy (NCT05866198)
- Testing
- Actigraph CP Insight Watch
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of South Florida
Stage 4 Pulmonary Sarcoidosis
Pulmonary Rehabilitation in Patients With Sarcoidosis
The primary objective of the study is to assess the improvement of daily activity in subjects with Stage IV Pulmonary Sarcoidosis one year after the conduct of a pulmonary rehabilitation program.
- Trial name
- NCT02044939
- Testing
- Pulmonary rehabilitation program
- Where
- 11 sites in France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Lille
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Obstructive Airway Disease
Study of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture
The purpose of this study is to evaluate the efficacy and safety of four interventional pulmonology techniques for the treatment of fibrotic central airway stricture.
- Trial name
- NCT02287389
- Testing
- balloon dilation, cryotherapy, spiculiform electrosurgery
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Tang-Du Hospital
Interstitial Lung Disease
Effects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease
Exercise training as part of a structured pulmonary rehabilitation program is a key factor in improving quality of life and symptoms in people with interstitial lung disease (ILD).
- Trial name
- NCT04299945
- Testing
- concentrated beetroot juice (400mg of nitrate per serving), concentrated beetroot juice (trace amounts of nitrate per serving)
- Where
- 2 sites in Canada
- Volunteers
- 15 people
- Sponsor
- University of British Columbia
Chronic Obstructive Pulmonary Disease, Bronchiectasis
Reducing Chronic Breathlessness in Adults by Following a Self-guided, Internet Based Supportive Intervention (SELF-BREATHE)
Background: Some health conditions make breathing difficult and uncomfortable. When this happens every day, it is called chronic breathlessness.
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchiectasis, Interstitial Lung Disease, Lung Cancer
- Trial name
- SELF-BREATHE (NCT06326957)
- Testing
- SELF-BREATHE
- Where
- United Kingdom
- Volunteers
- 246 people
- Sponsor
- King's College Hospital NHS Trust
Fibrotic Interstitial Lung Disease
PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial
The fibrotic interstitial lung diseases (fILD) are characterised by lung scarring, distressing breathlessness and poor health-related quality of life.
- Trial name
- PFOX (NCT03737409)
- Testing
- Ambulatory Oxygen Therapy
- Where
- Australia
- Volunteers
- 116 people
- Sponsor
- Monash University
Pulmonary Fibrosis
An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using eHealth Technology
The I-FILE study is a prospective multicenter, multinational observational study where the feasibility of a patient-led registry using home monitoring in patients with pulmonary fibrosis will be evaluated.
- Trial name
- I-FILE (NCT04304898)
- Testing
- Home spirometry
- Where
- 2 sites in Netherlands
- Volunteers
- 700 people
- Sponsor
- Erasmus Medical Center
Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans (BO)
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation.
- Trial name
- NINBOST2018 (NCT03805477)
- Testing
- Nintedanib
- Where
- 3 sites in Saudi Arabia, Switzerland
- Volunteers
- 20 people
- Sponsor
- University Hospital, Basel, Switzerland
Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease, Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- OPTIMIZE-ILD-1 (NCT07482917)
- Testing
- Standard ILD Diagnostic Pathway, Optimized ILD Diagnostic Circuit
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Hospital de Granollers
Post-COVID-19 Syndrome, Lung Fibrosis
Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis
In this study we aim to evaluate the radiological and functional changes in post-acute covid-19 pulmonary fibrosis patients in relation to anti-inflammatory and/or antifibrotic drugs prescribed during and after covid-19 pneumonia.
- Trial name
- NCT05648734
- Testing
- Corticosteroids alone, Corticosteroids + Colchicine, Corticosteroids + Pirfenidone
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Mansoura University
Novel Coronavirus-induced Lung Fibrosis
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia
The antifibrotic agents, namely pirfenidone and nintedanib have been found to be effective in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- PINCER (NCT04856111)
- Testing
- Pirfenidone, Nintedanib
- Where
- India
- Volunteers
- 48 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh